The panel that advises the Food and Drug Administration on vaccines rejected the use of a booster dose of the Pfizer COVID-19 vaccine in people younger than 65 on Friday.
Pfizer had petitioned the FDA to approve a third dose of the two-shot vaccine for use in those ages 16 to 65 in the United States about six months after receiving the second dose of the vaccine, but the FDA’s Vaccines and Related Biological Products Advisory Committee voted 16-2 to deny the petition, citing a lack of evidence to show the clear benefit of administering the booster shots to patients with fully functional immune systems. The committee did end up approving third doses of the Pfizer vaccine for people ages 65 and older, the group deemed most susceptible to serious complications and even death due to the disease.